Basic & Clinical Medicine ›› 2020, Vol. 40 ›› Issue (5): 621-626.

• Original Articles • Previous Articles     Next Articles

Preliminary study on the mechanism of RNA-binding protein as a drug target of clofoctol

ZHANG Mei-lian1, WANG Zhi-xing1, HU Yan1, RAN Kun-nian1, HAN Wei1*, PENG Xiao-zhong1,2*   

  1. 1. State Key Laboratory of Medical Molecular Biology, Department of Molecular Biology and Biochemistry, Medical Primate Research Center, Neuroscience Center, Institute of Basic Medical Sciences CAMS, School of Basic Medicine PUMC, Beijing 100005;
    2. Institute of Medical Biology, Chinese Academy of Medical Sciences, Kunming 650118, China
  • Received:2020-01-14 Revised:2020-03-18 Online:2020-05-05 Published:2020-04-30
  • Contact: *pengxiaozhong@pumc.edu.cn; hanwei2012@ibms.pumc.edu.cn

Abstract: Objective To explore the molecular mechanism of anti-glioma by clofoctol targeting on RNA-binding proteins. Methods Biotin pull-down experiments were used to detect the binding of RNA-binding protein UNR (upstream of N-ras) to the target gene Krüppel-like factor 13(KLF13) mRNA fragments, and the effect of clofoctol on the binding to UNR to KLF13 mRNA fragments; The results of clofoctol DARTS sample's mass spectrometry combined with transcriptome chip analysis were used to screen other RNA-binding protein targets and to predict other downstream target genes. Results Clofoctol enhanced the interaction between UNR and the fragment of KLF13 mRNA; Clofoctol also acted on other RNA-binding proteins, and functioned in mTOR signaling pathway and TNF-related apoptosis-inducing ligand (TRAIL)-activated apoptotic signaling pathway. Conclusions Clofoctol can resist gliomas by acting on RNA-binding proteins.

Key words: clofoctol, glioma, UNR, KLF13 mRNA, RNA-binding proteins

CLC Number: